Provider: View Press Release
Type: Link
Title: GSK tops Access to Medicine Index (ATMI) for eighth consecutive time | GSK
Description: Company also announces £100 million investment over next ten years to support access initiatives in lower income countries
Provider: View Press Release
Type: Link
Title: GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis | GSK
Description: Results demonstrate the potential for this asset to be a component of simpler TB treatment regimens in the future.
Provider: View Press Release
Type: Link
Title: GSK provides an update on Zejula (niraparib) US prescribing information | GSK
Description: Zejula is an oral, once-daily PARP inhibitor currently being evaluated in multiple pivotal trials.
Provider: View Press Release
Type: Link
Title: Positive data for bepirovirsen from B-Clear phase IIb trial presented at American Association for the Study of Liver Diseases’ Meeting with simultaneous publication in the New England Journal of Medicine | GSK
Description: Phase III trial evaluating bepirovirsen to start in H1 2023.
Provider: View Press Release
Type: Link
Title: GSK provides update on DREAMM-3 phase III trial for Blenrep in relapsed/refractory multiple myeloma | GSK
Description: DREAMM-3 did not meet its primary endpoint of progression-free survival (PFS)
Provider: View Press Release
Type: Link
Title: EAGLE-2 and EAGLE-3 phase III trials for gepotidacin stopped early for efficacy following pre-planned interim analysis by Independent Data Monitoring Committee | GSK
Description: Gepotidacin could be the first new novel oral antibiotic treatment for uncomplicated urinary tract infections in over 20 years